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Abstract
Introduction Genomic and transcriptomic alterations affecting
key cellular processes such us cell proliferation, differentiation
and genomic stability are considered crucial for the
development and progression of cancer. Most invasive breast
carcinomas are known to derive from precursor in situ lesions. It
is proposed that major global expression abnormalities occur in
the transition from normal to premalignant stages and further
progression to invasive stages. Serial analysis of gene
expression (SAGE) was employed to generate a comprehensive
global gene expression profile of the major changes occurring
during breast cancer malignant evolution.
Methods In the present study we combined various normal and
tumor SAGE libraries available in the public domain with sets of
breast cancer SAGE libraries recently generated and
sequenced in our laboratory. A recently developed modified t
test was used to detect the genes differentially expressed.
Results We accumulated a total of approximately 1.7 million
breast tissue-specific SAGE tags and monitored the behavior of
more than 25,157 genes during early breast carcinogenesis.
We detected 52 transcripts commonly deregulated across the
board when comparing normal tissue with ductal carcinoma in
situ, and 149 transcripts when comparing ductal carcinoma in
situ with invasive ductal carcinoma (P < 0.01).
Conclusion A major novelty of our study was the use of a
statistical method that correctly accounts for the intra-SAGE
and inter-SAGE library sources of variation. The most useful
result of applying this modified t statistics beta binomial test is
the identification of genes and gene families commonly
deregulated across samples within each specific stage in the
transition from normal to preinvasive and invasive stages of
breast cancer development. Most of the gene expression
abnormalities detected at the in situ stage were related to
specific genes in charge of regulating the proper homeostasis
between cell death and cell proliferation. The comparison of in
situ  lesions with fully invasive lesions, a much more
heterogeneous group, clearly identified as the most importantly
deregulated group of transcripts those encoding for various
families of proteins in charge of extracellular matrix remodeling,
invasion and cell motility functions.
Keywords: breast cancer, gene expression profiling, serial analysis of gene expression
Introduction
Invasive ductal breast carcinoma (IDC) is the most com-
mon malignancy of the breast, accounting for ~80% of all
invasive breast tumors [1]. Although an issue of much con-
troversy over the years, there is now general agreement and
overwhelming histopathological and genetic evidence indi-
cating that most invasive breast carcinomas appear to
develop gradually from defined precursor lesions [2]. How-
ever, it also became clear that progression toward more
aggressive phenotypes is not obligatory [3]. It is further evi-
dent that many genetic abnormalities underlying tumor pro-
gression are probably phenotypically silent.
Numerous molecular genetic changes have been reported
as relevant in human breast carcinogenesis, such as anom-
alies affecting cell proliferation, apoptosis and invasion [4].
Preinvasive breast lesions such as high-grade ductal carci-
noma in situ (DCIS) are known to have acquired a myriad
DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; NF = nuclear factor; SAGE = serial analysis of gene expression; TNF = tumor 
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of genomic and transcriptomic changes, but as their name
implies they are not yet invasive. The development of the
ability to invade surrounding tissues is perhaps the most
critical event in cancer progression. Among proposed inva-
sion-related genes with reported altered expression in
tumor cells are cell adhesion molecules, proteases and
cytoskeletal molecules that may influence motility [5]. Iden-
tifying the key and most common gene expression abnor-
malities involved in the transition steps from preinvasion to
a fully invasive phenotype is an extremely important topic of
research and the main objective of the present report.
Studies on this area may provide clues to better diagnose
premalignant lesions at high risk of progression and may
aid in achieving a better understanding of critical early
molecular mechanisms involved in breast cancer evolution.
Serial analysis of gene expression (SAGE) is a comprehen-
sive profiling method that allows for global, unbiased and
quantitative characterization of transcriptomes [6,7]. SAGE
provides a statistical description of the mRNA population
present in a cell without prior selection of the genes to be
studied, and this constitutes a major advantage. In this
sense, only open systems can identify expressed genes
that have not yet been cloned or partially sequenced. A
second major advantage is that the information generated
is digital in format, and can be directly compared with data
generated from any other laboratory or with data available
in public databases such as the Cancer Genome Anatomy
Project http://cgap.nci.nih.gov/SAGE.
To perform a comparative SAGE analysis of normal, prein-
vasive and invasive lesions, we used a modified t test that
we have recently developed [8]. This method has the
advantage of taking into account both the intra-sample and
inter-sample variability, identifying 'common patterns' of
gene changes systematically occurring across samples.
Most of the tests developed for measuring differential
expression in SAGE data focus on capturing the first type
of variation correctly, but tend to neglect the second type
[9,10]. The aim of the present study was to provide a sta-
tistically robust global gene expression analysis on the pro-
gression of breast cancer using the described statistical
approach comparing breast normal and tumor SAGE librar-
ies obtained from public databases combined with addi-
tional SAGE libraries recently generated in our laboratory.
Materials and methods
SAGE libraries
To perform the comparative analysis of different stages of
breast cancer progression, we combined SAGE libraries
available in public databases with breast cancer libraries
generated and sequenced at our own laboratory. To this
end, 12 SAGE libraries of breast tissues (four normal
breast tissues, six DCIS tissues and two IDC tissues) were
downloaded from the Cancer Genome Anatomy Project –
SAGE Genie database (libraries generated at the Polyak
Laboratory, Dana-Farber Cancer Institute, Boston, MA,
USA). We used 11 additional breast cancer SAGE libraries
generated by ourselves, at an approximate resolution of
100,000 SAGE tags per library. All IDC SAGE libraries
used in this study were from lymph node-negative, estrogen
receptor-positive and progesterone receptor-positive
tumor samples, with a tumor size classification of T1 or T2
(i.e. T1–T2 N0 M0). Table 1 summarizes all the SAGE
libraries used in this comparative analysis.
SAGE methodology
For the SAGE libraries generated in our laboratory we fol-
lowed standard methods. Briefly, total RNA was extracted
from snap-frozen tissues using TRIzol (Invitrogen, San Fran-
cisco, CA, USA). SAGE library construction was per-
formed with the I-SAGE kit (Invitrogen) according to the
manufacturer's protocol and introducing only minor modifi-
cations. The anchoring enzyme was NlaIII and the tagging
enzyme used was BsmFI. Concatemerized ditags were
cloned into pZERO-1 and sequenced with an ABI 3700
DNA Analyzer (Applied Biosystems, Foster City, CA, USA).
SAGE data processing
SAGE tags were extracted from sequencing files using the
SAGE2000 software version 4.0 (a kind gift from Dr K. Kin-
zler, John Hopkins School of Medicine, Baltimore, MD,
USA). Tag abundances for all libraries were normalized to
a total of 100,000 tags (at which level a tag present 10
times has an abundance of 0.01%). Tag to gene assign-
ments as well as additional annotations using public data-
bases (e.g. Gene Ontology, Locus Link, Unigene cluster)
were performed, using web-based SAGE library tools
developed by ourselves http://spi.mdacc.tmc.edu/bitools/
about/sage_lib_tool.html. In our comparison we used only
tags with only one reliable assigned gene.
Statistical analysis of SAGE libraries
To compare the 23 SAGE libraries, we utilized a modified t
test recently developed by us [8]. This analysis allowed us
to identify SAGE tags with significantly different expression
levels (P < 0.01) between normal tissue and DCIS and
between DCIS and IDC. Tags with total counts of less than
three in all libraries were filtered out before the analysis. In
order to enable visualization and illustration of our analyses,
we utilized the TIGR MultiExperiment Viewer (MeV 2.2)
software (The Institute for Genomic Research, Rockville,
MD, USA). This tool was employed for normalization and
average clustering of the SAGE data.
The aim of the heat maps presented is simply to organize
and illustrate the data by graphical means. Briefly, the nor-
malization included logarithmic transformation followed by
median centering by samples and genes. We used stand-
ard average hierarchical clustering techniques to classifyAvailable online http://breast-cancer-research.com/content/6/5/R499
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and illustrate further the differences found by the modified
t test, showing the clusters of differentially coexpressed
genes between the normal tissue, DCIS and IDC groups.
Results and discussion
Generation and analysis of SAGE libraries
The primary goal of our study was to identify the most com-
monly occurring transcriptome changes in the transition
from normal breast epithelium to DCIS and invasive carci-
noma. To this end, SAGE data obtained from 11 breast
cancer libraries generated in our laboratory (1,090,815
tags) were combined and compared with data available in
the public domain (661,863 tags), thus generating a data-
set of almost 1.7 million breast cancer and normal specific
tags, representing approximately 25,157 transcripts from a
total of 23 libraries (Table 1).
Our statistically stringent analysis revealed 52 transcripts
commonly deregulated across the board when comparing
normal tissue with DCIS (Fig. 1), and 149 transcripts when
comparing DCIS with IDC (P < 0.01) (Fig. 2) (see addi-
tional data files 1 and 2 for additional information with sta-
tistical cutoff at P  < 0.05). Selected genes based on
relative abundance, highly statistical differences and high
fold changes between compared groups are sorted and
represented in Tables 2 and 3.
Table 1
Breast-specific serial analysis of gene expression (SAGE) libraries
Histology Library name Tag count Unique tags
Normal breast tissue
Normal 1 SAGE breast normal AP Br Na 37,419 15,886
Normal 2 SAGE breast normal epithelium AP 1a 49,021 18,276
Normal 3 SAGE breast normal organoid Ba 58,326 19,602
Normal 4 SAGE breast normal organoid B2a 59,481 20,391
Ductal carcinoma in situ
DCIS 1 SAGE breast carcinoma MD DCISa 42,174 14,237
DCIS 2 SAGE breast carcinoma AP DCIS 3a 57,924 31,142
DCIS 3 SAGE breast carcinoma B DCIS 4a 60,699 20,224
DCIS 4 SAGE breast carcinoma B DCIS 5a 43,118 15,935
DCIS 5 SAGE breast carcinoma epithelium AP DCIS 6a 73,409 30,256
DCIS 6 SAGE breast carcinoma B BWHT18a 50,879 19,182
DCIS 7 MDACC 22Tb 102,533 33,305
Invasive ductal carcinoma
IDC 1 MDACC 09Tb 91,647 37,863
IDC 2 MDACC 14Tb 100,255 26,422
IDC 3 MDACC 15Tb 90,198 27,653
IDC 4 MDACC 17Tb 100,386 29,300
IDC 5 MDACC 18Tb 101,543 29,936
IDC 6 MDACC 19Tb 100,334 28,498
IDC 7 MDACC 20Tb 100,047 28,903
IDC 8 MDACC 21Tb 103,825 31,412
IDC 9 MDACC 24Tb 99,546 30,363
IDC 10 MDACC 25Tb 100,501 30,778
IDC 11 SAGE breast carcinoma B IDC 3a 68,937 22,732
IDC 12 SAGE breast carcinoma B IDC 5a 60,476 20,457
Total 23 breast libraries 1,752,678
a Libraries available in public databases. b Libraries generated in our laboratory.Breast Cancer Research    Vol 6 No 5    Abba et al.
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As expected, we detected various ribosomal genes among
the most abundant transcripts in all the breast SAGE librar-
ies, and these genes were highly upregulated in the inva-
sive carcinomas. This agrees with the previous global
expression profiles and with the comparisons of cancers
and the corresponding normal tissues in general [7,11,12].
To simplify illustration of the data, ribosomal genes are not
included in the figures and tables.
Global comparison of normal tissues and DCIS
Among the 52 transcripts detected as differentially
expressed in DCIS (P < 0.01), 36 were downregulated
transcripts and 16 were upregulated transcripts in these
lesions when compared with normal breast epithelial cells
and mammary epithelial organoids (Fig. 1 and Table 2). We
defined and classified the 52 genes differentially expressed
into the nine functional categories [13] shown in Fig. 3a.
Interestingly, we found that 38% of these transcripts are
related to the cell cycle (15%), signal transduction (8%)
and apoptosis (15%).
As expected, our analysis of DCIS versus normal breast
epithelium revealed numerous similarities with SAGE data
reported previously [12,14], but more importantly it also
provided novel information. The expression of numerous
genes was significantly downregulated in DCIS, including:
transmembrane 4 super family member 1 (TM4SF1),
nuclear factor kappa light polypeptide (NFKB1A), pre-B-
cell  (PBEF),  RAS dexamethasone-induced (RASD1),
tumor necrosis factor receptor superfamily member 10b
(TNFRSF10B), and tumor necrosis factor α-induced pro-
tein (TNFAIP). All these transcripts were also observed
downregulated in previous reports [12,14] (Table 2). On
the contrary, our analysis revealed additional clusters of
genes significantly downregulated in the DCIS group that
were not previously reported by others: clusterin/apolipo-
protein J (CLU), nuclease sensitive element binding pro-
tein 1 (NSEP1),  lipopolysaccharide-induced TNF factor
(LITAF/PIG7),  basic leucine zipper/W2 domains 1
(BZW1), and cyclin L1 (CCNL1) (Table 2).
Clusterin was one of the most dramatically downregulated
genes (-63.9-fold; P = 0.0036) in DCIS libraries. This gene
encodes a heterodimeric, highly conserved, secreted
glycoprotein. Alterations in Clusterin  expression and/or
protein maturation are linked to changes in tissue growth or
regression, which may be related to specific proapoptotic
or antiapoptotic protein isoforms [15]. Clusterin  was
reported as overexpressed during tissue and cell involution,
and was downregulated in esophageal squamous cell car-
cinoma and prostate carcinoma, suggesting that this
expression alteration could be a general phenomenon dur-
ing tumor progression [16,17]. On the contrary, and in con-
trast to these and our observations, Redondo and
colleagues reported increased Clusterin  expression in
Figure 1
Hierarchical clustering of the most commonly different expressed  genes between normal breast tissue and ductal carcinoma in situ  (DCIS) groups (P < 0.01) Hierarchical clustering of the most commonly different expressed 
genes between normal breast tissue and ductal carcinoma in situ 
(DCIS) groups (P < 0.01). Color scale at bottom of picture is used to 
represent expression level: low expression is represented by green, and 
high expression is represented by red.Available online http://breast-cancer-research.com/content/6/5/R499
R503
Figure 2
Hierarchical clustering of the most commonly differentially expressed genes between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma  (IDC) groups (P < 0.01) Hierarchical clustering of the most commonly differentially expressed genes between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma 
(IDC) groups (P < 0.01). Color scale at bottom of picture is used to represent expression level: low expression is represented by green, and high 
expression is represented by red.Breast Cancer Research    Vol 6 No 5    Abba et al.
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Table 2
Most frequent differentially expressed genes between normal breast epithelium and ductal carcinoma in situ (DCIS)
Tag Gene Description Locus link Fold change P value
DCIS overexpressed genes
GTATTTAACT PKD1-like Polycystic kidney disease 1-like 79932 13.7 0.0100
CGGACTCACT STARD10 START domain containing 10 10809 11.2 0.0086
GTGTTGGGGG EPS8L2 EPS8-like 2 64787 9.6 0.0099
TTTCTGGAGG KIAA0545 KIAA0545 protein 23094 8.6 0.0100
GATAAATTAA FLJ14153 Hypothetical protein 64747 8.5 0.0055
GAGAAATATC NP220 Nuclear protein 27332 8.0 0.0088
CCCTCTTTGG LOC118487 mRNA similar to RIKEN cDNA 1110001019 118487 7.4 0.0037
CTGGGACTGA LSM4 U6 small nuclear RNA associated (S. cerevisiae) 25804 6.4 0.0055
CTGGGCCAGC VAMP5 Vesicle-associated membrane protein 5 10791 6.4 0.0068
GCCCTTTCTC MRC2 Mannose receptor, C type 2 9902 5.8 0.0015
TCTTGATTTA A2M Alpha-2-macroglobulin 2 5.8 0.0083
TAGTTTGTGG MSH2 MutS homolog 2, colon cancer 4436 5.6 0.0091
TCAGTGAACT HPS4 Hermansky–Pudlak syndrome 4 89781 5.6 0.0100
GTTTATTCTT FOXA1 Forkhead box A1 3169 5.3 0.0044
GCCGCTGCCA PPP1R13B Protein phosphatase 1 23368 4.3 0.0054
TAAAGTGTCT PIGS Phosphatidylinositol glycan, class S 94005 3.9 0.0100
DCIS underexpressed genes
GGGACGAGTG TM4SF1 Transmembrane 4 superfamily member 1 4071 -442.6 0.0083
TAACAGCCAG NFKBIA Nuclear factor kappa light polypeptide gene 4792 -158.6 2.4 × 10-6
CAACTAATTC CLU Clusterin 1191 -63.9 0.0036
GCCTTAACAA PBEF Pre-B-cell colony-enhancing factor 10135 -44.3 0.0020
GGGTTTTTAT NSEP1 Nuclease sensitive element binding protein 1 4904 -36.2 0.0001
GACACGAACA RASD1 RAS, dexamethasone-induce 1 51655 -31.4 0.0095
AAGATTGGTG CD9 CD9 antigen (p24) 928 -29.6 0.0003
ACCAAATTAA TNFRSF10B Tumor necrosis factor receptor superfamily 8795 -29.4 0.0003
CTGGGCCTGA LITAF Lipopolysaccharide-induced tumor necrosis factor 9516 -28.9 0.0076
CTGCCATAAC SBDS Shwachman–Bodian–Diamond syndrome 51119 -24.2 0.0005
CACAGGCAAA BZW1 Basic leucine zipper and W2 domains 1 9689 -22.1 0.0056
GTTCCCTGGC FAU Finkel–Biskis–Reilly murine sarcoma virus 2197 -22.1 0.0028
GTCTGCACCT DKFZp547C1 Hypothetical protein 254851 -21.9 0.0087
TACGTTGCAG GC20 Translocation factor sui1 homolog 10289 -21.8 0.0079
TGTAAAGATT CCNL1 Cyclin L1 57018 -21.2 0.0008
TGTTAAGTTC CRY1 Cryptochrome 1 (photolyase-like) 1407 -18.7 0.0091
GAAATAAAGT FLJ21657 Hypothetical protein 64417 -18.5 0.0032
ATGGGCTTGA SQRDL Sulfide quinone reductase-like (yeast) 58472 -17.3 0.0061
TCAAGAAATT PSME3 Proteasome activator subunit 3 10197 -15.7 0.0028
CCGTGGTCGT FBL Fibrillarin 2091 -15.3 0.0100Available online http://breast-cancer-research.com/content/6/5/R499
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breast carcinoma samples [18]. The reason for this
discrepancy is unclear at this point. The role of Clusterin in
cell survival, cell death and neoplastic transformation
remains controversial [15].
Another commonly observed downregulated gene in DCIS
libraries was NSEP-1 (-36.2-fold; P = 0.0001). Also known
as YB1, NSEP-1 is a member of the highly conserved Y-
box family of proteins, which regulate the transcription of
several genes associated with cell death including both fas,
a cell death-associated receptor, and the tumor suppressor
gene p53 [19]. The decrease in expression of NSEP-1
transcripts could play an important role in the early stages
of breast carcinogenesis in order to overcome cell prolifer-
ation controls.
Interestingly, and as previously observed, we also detected
significant downregulation of various cytokines and chem-
okines: interleukin enhancer binding factor 2 (ILF2), inter-
leukin 13 receptor alpha 1 (IL13RA1), leukemia inhibitory
factor (LIF), cardiotrophin-like cytokine (CLC), chemokine
C–C ligand 2 (CCL2), and chemokine C–X–C ligand 1
(CXCL1). All these cytokines and chemokines are highly
expressed in normal mammary epithelium and are dramati-
cally downregulated in the DCIS samples. These differen-
tially expressed genes were detected within a range of
0.02 <P < 0.05 by means of the modified t test analysis.
These small secretory molecules, although usually linked to
inflammatory processes, could also play important auto-
crine and/or paracrine roles in the physiology of normal
mammary epithelial cells in particular because receptors for
these cytokines are also normally found expressed in nor-
mal breast epithelial cells [20]. Some of these molecules
(e.g. CXCL1, LIF) appear to play important roles in the nor-
mal periodic cycles of growth and involution of the mam-
mary gland following pregnancy and lactation. They may
thus be part of the physiologic mechanisms associated
with the massive apoptosis observed during involution
[21,22]. Unfortunately we understand very little of the rele-
vance of their intriguing de facto silencing in expression,
both in in situ as well as in invasive breast cancer lesions.
Interestingly, we also detected a series of transcripts com-
monly overexpressed in the DCIS samples: polycyctic kid-
ney disease 1-like (PKD1-like), START domain containing
10  (STARD10),  EPS8-like2  (EPS8L2), and KIAA0545
protein  (Fig. 1d). One of these genes, EPS8-like2,
encodes a protein that is related to epidermal growth factor
receptor pathway substrate 8 (EPS8), and was shown to
be essential in Ras/PI3K to Rac signaling [23]. PKD1-like
encodes a member of the polycystin protein family. Mem-
bers of this protein family may function in cell development
and morphology, and may modulate intracellular calcium
homoeostasis and other signal transduction pathways
[24,25]. Although the PKD1 gene has been associated
with cancer mechanisms, this homologous family member
has not been implicated in carcinogenesis processes to the
best of our knowledge. KIAA0545, also known as signal-
induced proliferation-associated 1 like 3 (SIPA1L3), is a
member of the Sipa1 family and encodes a protein bearing
a domain highly homologous to the catalytic region of
human Rap1 GTPase-activating protein (Rap1GAP).
TGGAACAGGA TGIF Transforming growth factor beta-induced factor (TALE family 
homeobox)
7050 -12.2 0.0030
AATGCTGGCA DNAJB6 DnaJ homolog, subfamily B, member 6 10049 -11.7 0.0065
AATGAGCAAC GBP2 Guanylate binding protein 2, interferon-inducible 2634 -11.1 0.0082
GACCTATCTC KIAA0992 Paladin 23022 -10.9 0.0092
AACTCTTGAA EIF3S3 Eukaryotic translation initiation factor 3 8667 -10.6 0.0082
GGGATTTTGT PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 5366 -10.6 0.0091
AAAGCAAAAA PTPN4 Protein tyrosine phosphatase, non-receptor type 4 5775 -10.4 0.0040
ACTGACTATC NEU1 Sialidase 1 (lysosomal sialidase) 4758 -10.3 0.0095
TTCCAGTTCA PDE4B Phosphodiesterase 4B, camp-specific 5142 -9.9 0.0087
GAATGATTTC ORF1-FL49 Putative nuclear protein 84418 -9.5 0.0070
GACTCGCTCC HSJ001348 cDNA for differentially expressed CO16 gene 54742 -9.5 0.0072
TGGTTACAAA NDEL1 Nude nuclear distribution gene E homolog like 1 81565 -8.9 0.0100
AGTATGAGGA TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 7128 -8.1 0.0083
CAGTTTAAAA CRSP6 Cofactor required for Sp1 transcriptional activation 9440 -7.7 0.0100
Table 2 (Continued)
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Table 3
Most frequent differentially expressed genes between ductal carcinoma in situ and invasive ductal carcinoma (IDC)
Tag Gene Description Locus link Fold change P value
IDC overexpressed genes
TGGAAATGAC COL1A1 Collagen type I, alpha 1 1277 315.4 0.0054
ATGTGAAGAG SPARC Secreted protein, cysteine-rich (osteonectin) 6678 286.8 0.0003
TTTGGTTTTC COL1A2 Collagen type I, alpha 2 1278 210.9 0.0084
TTGCTGACTT COL6A1 Collagen type VI, alpha 1 1291 73.9 0.0023
TTATGTTTAA LUM Lumican 4060 56.7 0.0011
TTGGAGATCT NDUFA4 NADH dehydrogenase (ubiquinone) 4697 56.4 0.0065
CCACAGGGGA COL3A1 Collagen type III, alpha 1 1281 49.4 0.0056
ATCTTGTTAC FN1 Fibronectin 1 2335 44.3 0.0031
TTGTAATCGT OAZ1 Ornithine decarboxylase antizyme 1 4946 38.6 0.0038
TGTAATCAAT HNRPA1 Heterogeneous nuclear ribonucleoprotein A1 3178 38.2 0.0039
GGAAGCTAAG OSF-2 Osteoblast specific factor 2 (fasciclin I-like) 10631 36.3 0.0005
ACCTGTATCC IFITM3 Interferon induced transmembrane protein 3 10410 34.3 0.0021
GGAAATGTCA MMP2 Matrix metalloproteinase 2 4313 29.1 0.0008
TGCACTTCAA SPARCL1 SPARC-like 1 (mast9, hevin) 8404 21.7 0.0050
GGAACTTTTA SULF2 Sulfatase 2 55959 19.8 0.0017
CTGTTAGTGT MDH1 Malate dehydrogenase 1 4190 18.5 0.0026
TATGAATGCT CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 1462 18.2 0.0017
TCCAAATCGA VIM Vimentin 7431 17.7 0.0014
TGTAGTTTGA SKP1A S-phase kinase-associated protein 1A 6500 16.9 0.0013
TAATAAACAG ASAH1 n-Acylsphimgosine amidohydrolase 427 16.8 0.0085
GCCTCCTCCC EIF3k Eukaryotic translation initiation factor 3 27335 16.8 0.0098
GAAACAAGAT PGK1 Phosphoglycerate kinase 1 5230 15.8 0.0006
TGCTTTGGGA TTC11 tetratricopeptide repeat domain 11 51024 15.8 0.0018
GAAATCAAAA SIGLEC5 Sialic acid binding Ig-like lectin 5 8778 14.7 0.0098
ATGTAGTAGT HNRPD Heterogeneous nuclear ribonucleoprotein D 3184 14.7 0.0025
GACCACCTTT MFAP2 Microfibrillar-associated protein 2 4237 14.4 0.0000
ACTTATTATG DCN Decorin 1634 13.9 0.0007
TCTCTACCCA APLP2 Amyloid beta (A4) precursor-like protein 2 334 13.7 0.0076
TGCAATATGC FBN1 Fibrillin 1 2200 13.5 0.0037
ATTTCTTCAA SFRP2 Secreted frizzled-related protein 2 6423 13.4 0.0030
ATAAAAAGAA CTSK Cathepsin K (pycnodysostosis) 1513 13.0 0.0003
GTACATTGTA MGC15737 Hypothetical protein 85012 12.6 0.0011
TGATGTTTGA DAZAP2 DAZ associated protein 2 9802 12.5 0.0013
TCCGTGGTTG BASP1 Membrane attached signal protein 1 10409 12.1 0.0055
ACTGCTTTAC DKFZp564I1922 Adlican 25878 12.0 0.0086
TCTGCAATGA TINP1 Trasnforming growth factor beta-inducible nuclear protein 1 10412 12.0 0.0033
GTTTCTTCCC SELH Selenoprotein H 2880636 11.8 0.0037Available online http://breast-cancer-research.com/content/6/5/R499
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Sipal1 is involved in the regulation of the Ras-mediated sig-
nal transduction pathway for cell proliferation and cell cycle
progression [26]. These genes could be involved in
signaling pathways that lead to cell proliferation, but their
potential role in malignant transformation remains unknown.
Differentially expressed genes associated with NF-κB 
and tumor necrosis factor pathways
One of the transcripts observed to be most differentially
expressed when comparing normal tissue with DCIS was
NFKBIA (better known as IκBα), demonstrating a 150-fold
higher expression (P < 0.0001) in normal mammary epithe-
lial cells (Table 2 and Fig. 1b). NFKBIA is a member of IκB
family genes that play a critical role in regulating the activity
of the NF-κB transcription factor [27,28]. NF-κB plays a
major role in diverse biological processes such as cell pro-
liferation, differentiation, apoptosis and metastasis [29,30].
NF-κB is also required to prevent cell death induced by
tumor necrosis factor (TNF) [31].
Interestingly, and perhaps pointing to connected pathways
and related outcomes, we also detected a strong decrease
in the expression levels of TNFRSF10  (29-fold;  P  <
0.0003), LITAF/PIG7 (29-fold; P < 0.0003) and TNFAIP3
(eightfold; P < 0.0083) transcripts in the DCIS group. The
protein encoded by TNFRSF10, also known as TRAIL/
APO2, is a member of the TNF-receptor superfamily and
contains an intracellular death domain. This receptor can
be activated by TNF-related apoptosis inducing ligand and
its role is to transduce apoptosis signals [32,33]. LITAF/
PIG7, a transcription factor, termed lipopolysaccharide-
induced TNF-alpha factor, also found downregulated, was
reported to regulate TNF-alpha gene expression playing a
major role in TNF-alpha activation [34]. This gene, also
known as P53-induced gene 7 (PIG7), has been shown to
be induced by p53 when apoptosis is triggered, and there-
fore could also play a role in programmed cell death [35].
The concerted decline of these transcripts early in breast
tumor progression appears conducive to a virtual silencing
of apoptosis induction pathways and a consequential net
increase in cell proliferation. In other words, the homeosta-
sis of proliferation cell death normally operating in the
breast epithelium is altered and inclined towards a net gain
in cell numbers via multiple signaling pathways.
Global comparison of in situ and invasive carcinomas
We found 149 transcripts differentially expressed between
DCIS and IDC at P < 0.01. All of these genes were found
overexpressed commonly at the invasive stage (Fig. 2).
Table 2 summarizes the 52 most commonly overexpressed
genes in invasive carcinoma lesions. We defined and clas-
sified the 149 genes differentially expressed in 10 func-
tional categories [13] as shown in Fig. 3b. Interestingly, we
found that 37% of these upregulated transcripts are related
to the cell cycle (12%), extracellular matrix or secreted pro-
teins (13%), cell adhesion and motility (6%), and signal
transduction (6%).
We were also able to detect 31 underexpressed genes in
invasive carcinomas when compared with DCIS, but only
when the stringency of the statistical comparison was
dropped to within the 95% confidence interval (i.e. P <
AATATGCTTT ATP6V1E1 ATPase 529 11.6 0.0009
TTATGGATCT SPON2 Spondin 2, extracellular matrix protein 10417 11.3 0.0003
AAAATAAAGA APEX1 Nuclease, multifunctional DNA repair enzyme 328 11.3 0.0099
TGTGTGTTTG HIF0 H1 histone family 3005 11.2 0.0029
TATGTTTCAG PTPN12 Protein tyrosine phosphatase 5782 11.1 0.0003
ACCAAAGCCC MGC9651 Hypothetical protein 114932 10.6 0.0075
CAAGGATCTA NICE-3 NICE-3 protein 25912 10.5 0.0057
GACGTCTTAA PSMA4 Proteasome subunit, alpha type 5685 10.3 0.0038
CAGATAACAT TOMM20 Translocase 9804 10.1 0.0064
AACTCTTGAA EIF3S3 Eukaryotic translation initiation factor 3 8667 10.0 0.0047
TTCTTGGTGT TRPS1 Trichorhinophalangeal syndrome I 7227 9.9 0.0042
TGCCTTAGTA DNAJC1 DNAJ homolog 64215 9.8 0.0040
AGACAAGCTG SFRS5 Splicing factor 6430 9.4 0.0015
ACAAGAATTG SYPL Synaptophysin-like protein 6856 9.3 0.0027
TACATCCGAA MTPN Myotrophin 136319 9.3 0.0013
Table 3 (Continued)
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0.05), reflecting a lower level of consistency in these gene
expression changes when comparing DCIS with IDC (Fig.
4). Examples of these genes include: transmembrane 4
superfamily member 1 (TM4SF1) (-26.7-fold; P = 0.04),
tumor necrosis factor receptor-associated factor 4
(TRAF4) (-10.7-fold; P  = 0.04), PPAR binding protein
(PPARBP) (-8.2-fold; P = 0.04), aldo-keto reductase fam-
ily 1 (AKR1A1) (-6.7-fold; P = 0.03), hypothetical protein
dJ465N24.2.1 (-6.4-fold; P = 0.028), microtubule-associ-
ated protein 1 (MAP1LC3A) (-3.7-fold; P  = 0.02) and
retinoblastoma binding protein 6 (RBBP6) (-2.6-fold; P =
0.04).
The first of these transcripts, TM4SF1, was also the most
dramatically downregulated gene in DCIS when compared
with normal breast libraries (-442.6-fold; P = 0.0083). The
transmembrane proteins TM4SF1, also known as the tet-
raspanin superfamily, are implicated in diverse signal trans-
duction events that play a role in the regulation of cell
development, cell proliferation, differentiation and motility
[36]. The tetraspanins  are associated with adhesion
receptors of the integrin  family and regulate integrin-
dependent cell migration [36]. In the present study, the loss
in gene expression of TM4SF1, from normal breast tissue
to invasive carcinomas, appears to be a common event in
the progression of breast carcinomas. In addition, down-
regulated levels of the TRAF4 transcript could cooperate in
the evolution from DCIS to invasive carcinomas. TRAF4 is
a proapoptotic gene member of the TRAF family of adaptor
proteins that mediate cellular signaling by binding to vari-
ous members of the tumor necrosis family receptor super-
family and interleukin-1/Toll-like receptor superfamily [37].
Interestingly, a recent study showed that overexpression of
TRAF4 can induce apoptosis, playing a role in p53-medi-
ated proapoptotic signaling in response to cellular stress
[38].
Differentially expressed genes related with extracellular 
matrix remodeling and invasion processes
During their metastatic conversion, epithelial carcinoma
cells acquire the ability to invade the surrounding tissues
and later disseminate to secondary organs mostly via
lymphatic vessels. The metastatic process is not just a
function of acquisition of novel migratory and invasive prop-
erties by the epithelial tumor cells; the surrounding stroma
also plays a critical role in this process [2]. Dramatic
changes take place in order to remodel the extracellular
matrix environment in response to the infiltrating cancer
cells (desmoplastic reaction) [39-41]. In this sense, we
identified high expression levels of several transcripts that
could be a reflection of the host stromal response, such as
collagen 1α1, collagen 1α2, collagen 3α1, collagen 6α1,
fibronectin I, fibrilli, microfibrillar-associated protein 2, and
Spondin 2.
It is known that the proteolytic degradation of the extracel-
lular matrix is more than the simple removal of a physical
barrier to invasion; such processes and the increased
expression of the involved genes are known to also signifi-
cantly influence mechanisms controlling cell proliferation
[42]. Matrix metalloproteinases are zinc-dependent
endopeptidases involved in matrix degradation and tissue
remodeling [43]. These endopeptidases are capable of
degrading both the extracellular matrix and basement mem-
brane, physical barriers that play important roles in prevent-
ing against expanding growth and migration of cancer cells
[44]. It is therefore widely accepted that overexpression of
matrix metalloproteinases is associated with cancer-cell
invasion and metastasis. A member of the matrix metallo-
proteinase family (MMP-2) was highly expressed (29.1-
fold; P = 0.0008) in IDC libraries in comparison with in situ
carcinomas. MMP-2 has been shown overexpressed in var-
ious human tumors, including breast cancer [45,46].
Figure 3
Classification in functional categories of affected transcripts Classification in functional categories of affected transcripts. (a) Differ-
entially expressed between normal breast tissue and ductal carcinoma 
in situ (DCIS) (P < 0.01). (b) Transcripts differentially expressed 
between DCIS and invasive ductal carcinoma (IDC) (P < 0.01).Available online http://breast-cancer-research.com/content/6/5/R499
R509
Figure 4
Hierarchical clustering of downregulated genes in invasive ductal carcinoma (IDC) (P < 0.05) Hierarchical clustering of downregulated genes in invasive ductal carcinoma (IDC) (P < 0.05). Color scale at bottom of picture is used to represent 
expression level: low expression is represented by green, and high expression is represented by red. DCIS, ductal carcinoma in situ.Breast Cancer Research    Vol 6 No 5    Abba et al.
R510
To no surprise and as observed in other studies, we also
detected significant increases in SPARC (286-fold; P =
0.0003) and a new related gene SPARC-like1 (21.7-fold;
P = 0.005) among the groups of genes upregulated in
invasive lesions. The SPARC gene encodes for a secreted
protein acid rich in cysteines also known as osteonectin
[47]. This protein is involved in a variety of diverse biologi-
cal processes including tissue remodeling, cell adhesion,
proliferation, differentiation, matrix synthesis/turnover, ang-
iogenesis and tumor cell migration and invasion [47]. Over-
expression of the SPARC  gene has been reported
associated with melanoma and metastatic carcinomas of
the breast, and increased SPARC expression has been
observed in conjunction with increased c-Jun and Fra-1
expression in a panel of invasive breast cancer cell lines
[48].
Human SPARC-like1, also known as mast9 or hevin, is a
member of the SPARC protein family. Interestingly, previ-
ous reports indicated downregulation of SPARC-like1 in
prostate and colon carcinomas [49,50]. Contrary to these
observations, we observed consistent high expression of
this transcript across all IDC libraries. Functional assays
suggest that SPARC-like1 may serve as an antagonist to
cell adhesion, playing a key role in the inhibition of attach-
ment, and may facilitate spreading of endothelial cells on
fibronectin substrates [51].
Taken together, these expression profiles suggest that
MMP-2, SPARC and SPARC-like1 are probably critical
mediators of extracellular matrix remodeling and are all
important in facilitating breast cancer invasion and
progression.
Other genes commonly expressed at high levels in invasive
carcinomas and of much lower expression in DCIS and nor-
mal breast tissues include lumican (LUM/LDC) (56.7-fold;
P = 0.0011), versican (CSPG2) (18.2-fold; P = 0.0017),
vimentin (VIM) (17.7-fold; P = 0.0014), decorin (DCN/
PG2) (13.9-fold; P  = 0.0007) and adlican
(DKFZp564I1922) (12-fold; P  = 0.0086). Lumican  and
decorin are members of the small leucine-rich proteoglycan
family of proteins [40]. Several studies have demonstrated
that small leucine-rich proteoglycan proteins can modulate
cellular behavior, including cell migration and proliferation
during tumor growth. Furthermore, the high expression
level of lumican was associated with high tumor grade and
was expressed specifically in breast cancer tissues, but not
in normal breast tissues, suggesting that lumican is differ-
entially expressed during breast tumor progression
[40,52]. These findings suggest that lumican may play an
important role in breast cancer growth.
Recent studies have suggested that expression of
increased amounts of versican, a chondroitin sulphate pro-
teoglycan, in neoplastic tissues may play a role in promot-
ing tumor cell proliferation and migration [53]. Abnormal
versican  deposition has been observed in a number of
tumor types, including breast cancer [54]. Furthermore, it
has been suggested that the versican-rich extracellular
matrices exert an anti-adhesive effect on cells, thus facilitat-
ing tumor-cell migration and invasion [55].
Figure 5
Schematic model portraying some of the most significant transcriptomic changes observed in breast cancer progression Schematic model portraying some of the most significant transcriptomic changes observed in breast cancer progression. DCIS, ductal carcinoma in 
situ; IDC, invasive ductal carcinoma.Available online http://breast-cancer-research.com/content/6/5/R499
R511
Vimentin  is a type III intermediate filament normally
expressed in cells of mesenchymal origin [56]. However,
numerous studies have now demonstrated that vimentin
can also be expressed in epithelial cells involved in physio-
logical or pathological processes requiring epithelial cell
migration [57]. Vimentin  has indeed been described in
migratory epithelial cells involved in embryological and org-
anogenesis processes and tumor invasion [58]. Also,
vimentin  antisense transfection in vimentin-expressing
breast cell lines was shown to reduce their in vitro invasive-
ness or migration, strongly emphasizing a functional contri-
bution of vimentin to epithelial cell invasion/migration [59].
Conclusions
Using comprehensive gene expression profiling by means
of SAGE combined with a recently developed statistical
approach, we identified the most consistent and statisti-
cally significant changes occurring in breast cancer pro-
gression detected by this methodology. A comparison of
the genes identified in our DCIS and IDC analysis with pre-
vious observations [11,12,14,41] revealed expected simi-
larities. More importantly, several genes were identified in
our analysis that were not previously reported or detected
in other SAGE studies. This suggests that the comparative
analysis we performed of normal breast tissue, DCIS and
invasive carcinomas by means of the modified t  test
appears statistically rigorous and applicable to SAGE stud-
ies in which multiple libraries are compared.
In the present study we observed that deregulation of
genes involved in the control of cell proliferation, apoptosis
and mammary gland development are frequently altered at
the  in situ stage (Fig. 5). Meanwhile, alterations in the
expression of genes related to the cell cycle and extracellu-
lar matrix remodeling (proteinases, collagenases, cysteine
proteinases), and several transcripts related to cell adhe-
sion and motility, were abundantly deregulated at the inva-
sive carcinoma stage (Fig. 5). Additional analysis and
validation of the identified genes will be required to deter-
mine the clinical value, and to determine whether they may
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